MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtcvs.2019.06.020

Медицинская библиотека · The Journal of thoracic and cardiovascular surgery · 2019

Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.

van Diepen Sean, Mehta Rajendra H, Leimberger Jeffrey D, Goodman Shaun G, Fremes Stephen, Jankowich Rachael, Heringlake Matthias, Anstrom Kevin J, Levy Jerrold H, Luber John, Nagpal A Dave, Duncan Andra E, Argenziano Michael, Toller Wolfgang, Teoh Kevin, Knight J David, Lopes Renato D, Cowper Patricia A, Mark Daniel B, Alexander John H

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеVideo-Audio MediaПеревод в очереди

Аннотация

OBJECTIVE

In the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial, no differences in clinical outcomes were observed between levosimendan and placebo in a broad population of patients undergoing cardiac surgery. In previous studies, the benefits of levosimendan were most clearly evident in patients undergoing isolated coronary artery bypass grafting (CABG) surgery. In a prespecified analysis of LEVO-CTS, we compared treatment-related outcomes and costs across types of cardiac surgical procedures.

METHODS

Overall, 563 (66.4%) patients underwent isolated CABG, 97 (11.4%) isolated valve, and 188 (22.2%) combined CABG/valve surgery. Outcomes included the co-primary 4-component composite (30-day mortality, 30-day renal replacement, 5-day myocardial infarction, or 5-day mechanical circulatory support), the 2-component composite (30-day mortality or 5-day mechanical circulatory support), 90-day mortality, low cardiac output syndrome (LCOS), and 30-day medical costs.

RESULTS

The 4- and 2-component outcomes were not significantly different with levosimendan and placebo in patients undergoing CABG (15.2% vs 19.3% and 7.8% vs 10.4%), valve (49.0% vs 33.3% and 22.4% vs 2.1%), or combined procedures (39.6% vs 35.9% and 24.0% vs 19.6%). Ninety-day mortality was lower with levosimendan in isolated CABG (2.1% vs 7.9%; hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.11-0.64), but not significantly different in valve (8.3% vs 2.0%; HR, 4.10; 95% CI, 0.46-36.72) or combined procedures (10.4% vs 7.6%; HR, 1.39; 95% CI, 0.53-3.64; interaction P = .011). LCOS (12.0% vs 22.1%; odds ratio, 0.48; 95% CI, 0.30-0.76; interaction P = .118) was significantly lower in levosimendan-treated patients undergoing isolated CABG. Excluding study drug costs, median and mean 30-day costs were $53,707 and $65,852 for levosimendan and $54,636 and $67,122 for placebo, with a 30-day mean difference (levosimendan - placebo) of -$1270 (bootstrap 95% CI, -$8722 to $6165).

CONCLUSIONS

Levosimendan was associated with lower 90-day mortality and LCOS in patients undergoing isolated CABG, but not in those undergoing isolated valve or combined CABG/valve procedures.

Для цитирования: van Diepen Sean, Mehta Rajendra H, Leimberger Jeffrey D, Goodman Shaun G, Fremes Stephen, Jankowich Rachael, Heringlake Matthias, Anstrom Kevin J, Levy Jerrold H, Luber John, Nagpal A Dave, Duncan Andra E, Argenziano Michael, Toller Wolfgang, Teoh Kevin, Knight J David, Lopes Renato D, Cowper Patricia A, Mark Daniel B, Alexander John H. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.. The Journal of thoracic and cardiovascular surgery. 2019. DOI: 10.1016/j.jtcvs.2019.06.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.